Day One Biopharmaceuticals Inc (OQ:DAWN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 395 Oyster Point Blvd Ste 217
Tel: N/A
IR: See website
Key People
Julie Grant
Chairman of the Board, Co-Founder
Jeremy Bender
President, Chief Executive Officer, Director
Samuel Blackman
Co-Founder, Chief Medical Officer
Charles N. York
Chief Financial Officer, Chief Operating Officer, Secretary
Business Overview
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers. It seeks to identify, acquires, and develops product candidates that target high-value oncogenic drivers in cancers with unmet need, with an initial focus on pediatric patients. Its lead product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Tovorafenib is also used for the treatment of low-grade gliomas (LGGs). Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a key signaling node in the MAPK pathway. It has initiated a phase II trial of tovorafenib for pediatric patients with relapsed or progressive low-grade glioma (pLGG), the common brain tumor diagnosed in children.
Financial Overview
For the six months ended 30 June 2022, Day One Biopharmaceuticals Inc revenues was not reported. Net loss decreased 50% to $64.3M. Lower net loss reflects Other expense decrease of 97% to $1K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.10 to -$1.08.
Employees: 94 as of Jun 30, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $1,276M as of Jun 30, 2022
Annual revenue (TTM): $0.00M as of Jun 30, 2022
EBITDA (TTM): -$105.66M as of Jun 30, 2022
Net annual income (TTM): -$105.46M as of Jun 30, 2022
Free cash flow (TTM): -$76.76M as of Jun 30, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 73,461,100 as of Aug 1, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.